- Home
- ONON vs QGEN Comparison
ONON vs QGEN Comparison
Compare ONON & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONON | QGEN |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | Switzerland | Netherlands |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.0B |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ONON | QGEN |
|---|---|---|
| Price | $35.00 | $50.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 31 | 12 |
| Target Price | $44.13 | ★ $49.59 |
| AVG Volume (30 Days) | ★ 9.8M | 5.6M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.59 | $2.18 |
| Revenue Next Year | $18.94 | $5.03 |
| P/E Ratio | $56.05 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.37 | $32.53 |
| 52 Week High | $51.08 | $57.82 |
Technical Indicators
Market Signals| Indicator | ONON | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 67.51 |
| Support Level | $31.11 | $50.07 |
| Resistance Level | $38.73 | $50.82 |
| Average True Range (ATR) | 1.39 | 0.27 |
| MACD | 0.10 | -0.13 |
| Stochastic Oscillator | 46.94 | 48.13 |
Price Performance
Historical ComparisonAbout ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).